What is the difference between Davunetide and Desmopressin?

Davunetide: Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation. Desmopressin: Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin

Is Davunetide FDA approved?

Davunetide is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Desmopressin FDA approved?

Desmopressin is FDA approved. This regulatory status is provided for research and educational context only.

How is Davunetide administered in research settings?

In research settings, Davunetide is typically administered via the intranasal or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

How is Desmopressin administered in research settings?

In research settings, Desmopressin is typically administered via the intranasal, oral, or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Davunetide vs Desmopressin

Peptide Comparison

Davunetide vs Desmopressin

Both are Neuro & Cognitive peptides.

Davunetide

NAP

CognitiveInvestigationalResearch Only

No providers listed yet

Full Davunetide profile →

Desmopressin

DDAVP

CognitiveFDA ApprovedPrescription

Half-life: 1.5-2.5 hours (intranasal)

2 providers listed

Full Desmopressin profile →

Bottom line

Desmopressin is FDA-approved, while Davunetide is investigational — the clearest structural difference between them.

Quick Verdict

Davunetide

Half-life

—

Desmopressin

Half-life

1.5-2.5 hours (intranasal)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Desmopressin
Further along in FDA review	Desmopressin
Oral administration option	Desmopressin
More provider options (0 vs 2)	Desmopressin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Davunetide

Desmopressin

Mechanism Family

Neuro & Cognitive

Half-life

—

1.5-2.5 hours (intranasal)

FDA Status

investigational

approved

Admin Routes

intranasal, subcutaneous

intranasal, oral, subcutaneous

Availability

Research Only

Prescription

Providers

None listed

2 listed

Avail. Notes

—

FDA-approved synthetic vasopressin analog. Brands: DDAVP (NDA 017922), Stimate, Nocdurna (NDA 201532, Jun 2018). Approved forms: injection, intranasal, oral, sublingual. Prescription only.

Research Evidence

Davunetide

RCT · 3 key studies · most recent 2026

Desmopressin

RCT · 5 key studies · most recent 2026

Research Citations

Davunetide

RCT2013 · Neuropsychopharmacology

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with sch…

RCT2011 · Schizophrenia Research

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophren…

Animal2026 · Epilepsy Res

Microtubule-stabilizing drugs suppress convulsions in a C. elegans model of CAMSAP disorders.

Desmopressin

RCT1995 · Peptides

Failure of posttrial administration of vasopressin analogue (DDAVP) to influence memory in healthy, young, ma…

Cohort2026 · Clinical Endocrinology

Clinical Outcomes Following Supply-Driven Transition From Intranasal to Oral Desmopressin in AVP-Deficiency

Case series2026 · Cureus

Adult-Onset Multisystem Langerhans Cell Histiocytosis: Atypical Skeletal and Endocrine Manifestations.

Case series2026 · Cureus

Central Diabetes Insipidus Following Steroid Replacement for Hypoadrenalism in Pembrolizumab-Induced Hypophys…

+1 more

About Davunetide

Stabilizes microtubules by interacting with tubulin and microtubule-associated proteins. Activates SIRT1, reduces amyloid-β toxicity, and enhances synaptic plasticity. Protects against tau hyperphosphorylation.

Research Areas

neuroprotectiontau stabilizationcognitive enhancementmemorysynaptic plasticity

About Desmopressin

Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin

Research Areas

memory consolidationlearning enhancementantidiuretichemostasis

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Davunetide

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Desmopressin

Reported (Unverified — Pending Clinical Review)

hyponatremiaheart failureuncontrolled hypertensionpsychogenic polydipsia

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Davunetide

Browse directory →

Providers offering

Desmopressin

2 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.